The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
From non-A, non-B hepatitis to hepatitis C virus cure
Open accessAbstract
The hepatitis C virus (HCV) was discovered in the late 1980s. Interferon (IFN)-α was proposed as an antiviral treatment for chronic hepatitis C at about the same time. Successive improvements in IFN-α-based therapy (dose finding, pegylation, addition of ribavirin) increased the rates of sustained virologic response, i.e. the rates of curing HCV infection. These rates were further improved by adding the first available direct-acting antiviral (DAA) drugs to the combination of pegylated IFN-α and ribavirin. An IFN-free era finally started in 2014, yielding rates of sustained virologic response over 90% in patients treated for 8 to 24 weeks with all-oral regimens. Major challenges however remain in implementation of these new treatment strategies, not only in low- to middle-income countries, but also in high-income countries where the price of these therapies is still prohibitive. Elimination of HCV infection through treatment in certain areas is possible but raises major public health issues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation of a cDNA cLone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis Genome
Choo, Q.-L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W., & Houghton, M. (1989) · Science · doi:10.1126/science.2523562 · Cited by 6,875
Prevention of HIV-1 infection with early antiretroviral therapy.
Cohen, M. S., Chen, Y. Q., McCauley, M., Gamble, T., Hosseinipour, M. C., Kumarasamy, N., Hakim, J. G., Kumwenda, J., Grinsztejn, B., Pilotto, J. H. S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105243 · Cited by 6,873
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales, F. L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020047 · Cited by 6,389
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,029
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
Ge, D., Fellay, J., Thompson, A. J., Simon, J. S., Shianna, K. V., Urban, T. J., Heinzen, E. L., Qiu, P., Bertelsen, A. H., Muir, A. J., et al. (2009) · Nature · doi:10.1038/nature08309 · Cited by 3,514
McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M.-H., Cort, S., & Albrecht, J. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392101 · Cited by 3,465
Hadziyannis, S. J., Sette, H., Morgan, T. R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H., Bernstein, D., Rizzetto, M., et al. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-5-200403020-00010 · Cited by 2,836
Self-citationEASL Recommendations on Treatment of Hepatitis C 2018
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.026 · Cited by 2,827
Self-citationBoceprevir for Untreated Chronic HCV Genotype 1 Infection
Poordad, F., McCone, J., Bacon, B. R., Bruno, S., Manns, M. P., Sulkowski, M. S., Jacobson, I. M., Reddy, K. R., Goodman, Z. D., Boparai, N., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010494 · Cited by 2,520
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Jacobson, I. M., McHutchison, J. G., Dusheiko, G., Di Bisceglie, A. M., Reddy, K. R., Bzowej, N. H., Marcellin, P., Muir, A. J., Ferenci, P., Flisiak, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012912 · Cited by 2,398
Self-citationPoynard, T., Marcellin, P., Lee, S. S., Niederau, C., Minuk, G. S., Ideo, G., Bain, V., Heathcote, J., Zeuzem, S., Trepo, C., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)07124-4 · Cited by 2,318
Self-citationHepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy
Neumann, A. U., Lam, N. P., Dahari, H., Gretch, D. R., Wiley, T. E., Layden, T. J., & Perelson, A. S. (1998) · Science · doi:10.1126/science.282.5386.103 · Cited by 2,113
Global epidemiology and genotype distribution of the hepatitis C virus infection
Gower, E., Estes, C., Blach, S., Razavi-Shearer, K., & Razavi, H. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.07.027 · Cited by 1,903
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Lawitz, E., Mangia, A., Wyles, D., Rodriguez-Torres, M., Hassanein, T., Gordon, S. C., Schultz, M., Davis, M. N., Kayali, Z., Reddy, K. R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214853 · Cited by 1,788
Lai, C. L., Ratziu, V., Yuen, M.-F., & Poynard, T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)15108-2 · Cited by 1,727
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Afdhal, N., Zeuzem, S., Kwo, P., Chojkier, M., Gitlin, N., Puoti, M., Romero-Gomez, M., Zarski, J.-P., Agarwal, K., Buggisch, P., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402454 · Cited by 1,705
Self-citationTreatment of Chronic Hepatitis C with Recombinant Interferon Alfa
Davis, G. L., Balart, L. A., Schiff, E. R., Lindsay, K., Bodenheimer, H. C., Perrillo, R. P., Carey, W., Jacobson, I. M., Payne, J., Dienstag, J. L., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911303212203 · Cited by 1,633
Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
Bacon, B. R., Gordon, S. C., Lawitz, E., Marcellin, P., Vierling, J. M., Zeuzem, S., Poordad, F., Goodman, Z. D., Sings, H. L., Boparai, N., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009482 · Cited by 1,626
Self-citationTelaprevir for Retreatment of HCV Infection
Zeuzem, S., Andreone, P., Pol, S., Lawitz, E., Diago, M., Roberts, S., Focaccia, R., Younossi, Z., Foster, G. R., Horban, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013086 · Cited by 1,546
Self-citationvan der Meer, A. J., Veldt, B. J., Feld, J. J., Wedemeyer, H., Dufour, J.-F., Lammert, F., Duarte-Rojo, A., Heathcote, E. J., Manns, M. P., Kuske, L., et al. (2012) · JAMA · doi:10.1001/jama.2012.144878 · Cited by 1,510
Self-citationLedipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Afdhal, N., Reddy, K. R., Nelson, D. R., Lawitz, E., Gordon, S. C., Schiff, E., Nahass, R., Ghalib, R., Gitlin, N., Herring, R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316366 · Cited by 1,307
Peginterferon Alfa-2a in Patients with Chronic Hepatitis C
Zeuzem, S., Feinman, S. V., Rasenack, J., Heathcote, E. J., Lai, M.-Y., Gane, E., O'Grady, J., Reichen, J., Diago, M., Lin, A., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012073432301 · Cited by 1,220
Self-citationRecombinant Interferon Alfa Therapy for Chronic Hepatitis C
Di Bisceglie, A. M., Martin, P., Kassianides, C., Lisker-Melman, M., Murray, L., Waggoner, J., Goodman, Z., Banks, S. M., & Hoofnagle, J. H. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911303212204 · Cited by 1,212
Self-citationDaclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
Sulkowski, M. S., Gardiner, D. F., Rodriguez-Torres, M., Reddy, K. R., Hassanein, T., Jacobson, I., Lawitz, E., Lok, A. S., Hinestrosa, F., Thuluvath, P. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306218 · Cited by 1,190
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
Kowdley, K. V., Gordon, S. C., Reddy, K. R., Rossaro, L., Bernstein, D. E., Lawitz, E., Shiffman, M. L., Schiff, E., Ghalib, R., Ryan, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402355 · Cited by 1,130
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Jacobson, I. M., Gordon, S. C., Kowdley, K. V., Yoshida, E. M., Rodriguez-Torres, M., Sulkowski, M. S., Shiffman, M. L., Lawitz, E., Everson, G., Bennett, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214854 · Cited by 1,090
Self-citationEASL Clinical Practice Guidelines: Management of hepatitis C virus infection
(2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.02.023 · Cited by 1,088
Peck, M., Craxì, A., Fried, M., & Zeuzem, S. (2013) · Cited by 1,079
Self-citationGhany, M. G., Nelson, D. R., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2011) · Hepatology · doi:10.1002/hep.24641 · Cited by 1,076
Outcomes of Treatment for Hepatitis C Virus Infection by Primary Care Providers
Arora, S., Thornton, K., Murata, G., Deming, P., Kalishman, S., Dion, D., Parish, B., Burke, T., Pak, W., Dunkelberg, J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009370 · Cited by 1,076
Treatment of Chronic Non-A, Non-B Hepatitis with Recombinant Human Alpha Interferon
Hoofnagle, J. H., Mullen, K. D., Jones, D. B., Rustgi, V., Di Bisceglie, A., Peters, M., Waggoner, J. G., Park, Y., & Jones, E. A. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612183152503 · Cited by 972
Self-citationProkunina-Olsson, L., Muchmore, B., Tang, W., Pfeiffer, R. M., Park, H., Dickensheets, H., Hergott, D., Porter-Gill, P., Mumy, A., Kohaar, I., et al. (2013) · Nature Genetics · doi:10.1038/ng.2521 · Cited by 928
Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
Feld, J. J., Kowdley, K. V., Coakley, E., Sigal, S., Nelson, D. R., Crawford, D., Weiland, O., Aguilar, H., Xiong, J., Pilot-Matias, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315722 · Cited by 903
Self-citationABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
Poordad, F., Hezode, C., Trinh, R., Kowdley, K. V., Zeuzem, S., Agarwal, K., Shiffman, M. L., Wedemeyer, H., Berg, T., Yoshida, E. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402869 · Cited by 874
Self-citationFeinstone, S. M., Kapikian, A. Z., & Purcell, R. H. (1973) · Science · doi:10.1126/science.182.4116.1026 · Cited by 865
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
(2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.11.003 · Cited by 855
Lawitz, E., Sulkowski, M. S., Ghalib, R., Rodriguez-Torres, M., Younossi, Z. M., Corregidor, A., DeJesus, E., Pearlman, B., Rabinovitz, M., Gitlin, N., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61036-9 · Cited by 818
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
Zeuzem, S., Dusheiko, G. M., Salupere, R., Mangia, A., Flisiak, R., Hyland, R. H., Illeperuma, A., Svarovskaia, E., Brainard, D. M., Symonds, W. T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316145 · Cited by 795
Self-citationResponse-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection
Sherman, K. E., Flamm, S. L., Afdhal, N. H., Nelson, D. R., Sulkowski, M. S., Everson, G. T., Fried, M. W., Adler, M., Reesink, H. W., Martin, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014463 · Cited by 750
ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV
Ferenci, P., Bernstein, D., Lalezari, J., Cohen, D., Luo, Y., Cooper, C., Tam, E., Marinho, R. T., Tsai, N., Nyberg, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402338 · Cited by 693
Transfusion-Associated Hepatitis Not Due to Viral Hepatitis Type A or B
Feinstone, S. M., Kapikian, A. Z., Purcell, R. H., Alter, H. J., & Holland, P. V. (1975) · New England Journal of Medicine · doi:10.1056/nejm197504102921502 · Cited by 690
Lindsay, K. L., Trepo, C., Heintges, T., Shiffman, M. L., Gordon, S. C., Hoefs, J. C., Schiff, E. R., Goodman, Z. D., Laughlin, M., Yao, R., et al. (2001) · Hepatology · doi:10.1053/jhep.2001.26371 · Cited by 668
(1997) · Hepatology · doi:10.1002/hep.510260701 · Cited by 569
Krugman, S. (1967) · JAMA · doi:10.1001/jama.200.5.365 · Cited by 556
New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges
Pawlotsky, J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.03.003 · Cited by 518
Self-citationRetreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
Zeuzem, S., Jacobson, I. M., Baykal, T., Marinho, R. T., Poordad, F., Bourlière, M., Sulkowski, M. S., Wedemeyer, H., Tam, E., Desmond, P., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1401561 · Cited by 517
Self-citationNon-A, non-B hepatitis. I. Recognition, epidemiology, and clinical features
Dienstag, J. L. (1983) · Gastroenterology · doi:10.1016/0016-5085(83)90336-0 · Cited by 500
Martin, N. K., Vickerman, P., Grebely, J., Hellard, M., Hutchinson, S. J., Lima, V. D., Foster, G. R., Dillon, J. F., Goldberg, D. J., Dore, G. J., et al. (2013) · Hepatology · doi:10.1002/hep.26431 · Cited by 488
Hézode, C., Fontaine, H., Dorival, C., Larrey, D. G., Zoulim, F., Canva, V., de Lédinghen, V., Poynard, T., Samuel, D., Bourlière, M., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.04.035 · Cited by 443
Self-citationYehia, B. R., Schranz, A. J., Umscheid, C. A., & Lo Re, V. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101554 · Cited by 440
Jacobson, I. M., Dore, G. J., Foster, G. R., Fried, M. W., Radu, M., Rafalsky, V. V., Moroz, L., Craxi, A., Peeters, M., Lenz, O., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60494-3 · Cited by 437
An Interferon-free Antiviral Regimen for HCV after Liver Transplantation
Kwo, P. Y., Mantry, P. S., Coakley, E., Te, H. S., Vargas, H. E., Brown, R., Gordon, F., Levitsky, J., Terrault, N. A., Burton, J. R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408921 · Cited by 404
Manns, M., Marcellin, P., Poordad, F., de Araujo, E. S. A., Buti, M., Horsmans, Y., Janczewska, E., Villamil, F., Scott, J., Peeters, M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60538-9 · Cited by 376
Andreone, P., Colombo, M. G., Enejosa, J. V., Koksal, I., Ferenci, P., Maieron, A., Müllhaupt, B., Horsmans, Y., Weiland, O., Reesink, H. W., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.04.045 · Cited by 365
Posttransfusion Hepatitis After Exclusion of Commercial and Hepatitis-B Antigen-Positive Donors
ALTER, H. J., HOLLAND, P. V., PURCELL, R. H., LANDER, J. J., FEINSTONE, S. M., MORROW, A. G., & SCHMIDT, P. J. (1972) · Annals of Internal Medicine · doi:10.7326/0003-4819-77-5-691 · Cited by 354
Viral hepatitis. New light on an old disease
Krugman, S. (1970) · JAMA · doi:10.1001/jama.212.6.1019 · Cited by 348
Hepatitis C in the United States
Holmberg, S. D., Spradling, P. R., Moorman, A. C., & Denniston, M. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmp1302973 · Cited by 317
Rein, D. B., Smith, B. D., Wittenborn, J. S., Lesesne, S. B., Wagner, L. D., Roblin, D. W., Patel, N., Ward, J. W., & Weinbaum, C. M. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-4-201202210-00378 · Cited by 302
Brillanti, S., Garson, J. A., Foli, M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90131-7 · Cited by 285
Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon α2a
Zeuzem, S., Lee, J., Herrmann, E., Fricke, J., Neumann, A. U., Modi, M., Colucci, G., & Roth, W. K. (2001) · Gastroenterology · doi:10.1053/gast.2001.24006 · Cited by 270
Self-citationAntiviral action of ribavirin in chronic hepatitis C
Pawlotsky, J., Dahari, H., Neumann, A. U., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.12.002 · Cited by 262
Self-citationHistorical epidemiology of hepatitis C virus (HCV) in selected countries
Bruggmann, P., Berg, T., Øvrehus, A. L. H., Moreno, C., Brandão Mello, C. E., Roudot‐Thoraval, F., Marinho, R. T., Sherman, M., Ryder, S. D., Sperl, J., et al. (2014) · Journal of Viral Hepatitis · doi:10.1111/jvh.12247 · Cited by 261
Hézode, C., Fontaine, H., Dorival, C., Zoulim, F., Larrey, D. G., Canva, V., de Lédinghen, V., Poynard, T., Samuel, D., Bourlière, M., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.03.051 · Cited by 259
Self-citationViral Hepatitis: New Light on an Old Disease
Krugman, S. (1970) · JAMA · doi:10.1001/jama.1970.03170190035005 · Cited by 216
Bruggmann, P., & Litwin, A. H. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit271 · Cited by 184
The Origin of Hepatitis C Virus
Simmonds, P. (2013) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-27340-7_1 · Cited by 183
EASL Recommendations on Treatment of Hepatitis C 2014
(2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.05.001 · Cited by 181
Lenz, O., Verbinnen, T., Fevery, B., Tambuyzer, L., Vijgen, L., Peeters, M., Buelens, A., Ceulemans, H., Beumont, M. G., Picchio, G., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.11.032 · Cited by 132
Lawitz, E., Poordad, F. F., Brainard, D. M., Hyland, R. H., An, D., Dvory‐Sobol, H., Symonds, W. T., McHutchison, J. G., & Membreno, F. E. (2014) · Hepatology · doi:10.1002/hep.27567 · Cited by 125
Hézode, C., Hirschfield, G. M., Ghesquière, W., Sievert, W., Rodriguez‐Torres, M., Shafran, S. D., Thuluvath, P. J., Tatum, H. A., Waked, I. A., Esmat, G., et al. (2014) · Gut · doi:10.1136/gutjnl-2014-307498 · Cited by 120
Self-citationA Prospective Study of Posttransfusion Hepatitis
Gocke, D. J. (1972) · JAMA · doi:10.1001/jama.219.9.1165 · Cited by 120
Rotermann, M., Langlois, K. A., Andonov, A. P., & Trubnikov, M. (2013) · PubMed · Cited by 76
HCV iatrogenic and intrafamilial transmission in Greater Cairo, Egypt
Jimenez, A. P., Eldin, N. S., Rimlinger, F., El-Daly, M. M., El-Hariri, H. M., El‐Hoseiny, M., Mohsen, A., Mostafa, A., Delarocque‐Astagneau, E., Abdel‐Hamid, M., et al. (2010) · Gut · doi:10.1136/gut.2009.194266 · Cited by 75
Koff, R. S. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00169-1 · Cited by 65
Mitruka, K., Thornton, K., Cusick, S. M., Orme, C., Moore, A. C., Manch, R. A., Box, T. D., Carroll, C., Holtzman, D. J., & Ward, J. W. (2014) · PubMed Central · Cited by 59
Dore, G. J., Lawitz, E., Hézode, C., Shafran, S. D., Ramji, A. S., Tatum, H. A., Taliani, G., Tran, A., Brunetto, M. R., Zaltron, S., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.10.007 · Cited by 58
Clinical implications of hepatitis C viral kinetics
Zeuzem, S. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80376-6 · Cited by 55
Self-citationCost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C
Miguel, R. S., Gimeno‐Ballester, V., Blázquez, A., & Mar, J. (2014) · Gut · doi:10.1136/gutjnl-2014-307772 · Cited by 55
The principles and feasibility of disease eradication
Dowdle, W. R., & Cochi, S. L. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.04.006 · Cited by 48
Lemoine, M., & Thursz, M. R. (2014) · Seminars in Liver Disease · doi:10.1055/s-0034-1371082 · Cited by 37
Wong, W. H. S., Luk, C. W., & Kidd, M. R. (2012) · Sexually Transmitted Infections · doi:10.1136/sextrans-2011-050170 · Cited by 16
Bray, J. H. (2016) · American Psychological Association eBooks · doi:10.1037/14772-026 · Cited by 9
Cited by
Liu, Z., Jiang, Y., Yuan, H., Fang, Q., Cai, N., Suo, C., Jin, L., Zhang, T., & Chen, X. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.12.001 · Cited by 823
Historical review of the causes of cancer
Blackadar, C. B. (2016) · World Journal of Clinical Oncology · doi:10.5306/wjco.v7.i1.54 · Cited by 389
Koh, C., Li, Q., & Liang, J. (2016) · Clinical Virology · doi:10.1128/9781555819439.ch54 · Cited by 321
Functional and genetic deconstruction of the cellular origin in liver cancer
Marquardt, J. U., Andersen, J. B., & Thorgeirsson, S. S. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4017 · Cited by 306
de Wispelaere, M., Du, G., Donovan, K. A., Zhang, T., Eleuteri, N. A., Yuan, J. C., Kalabathula, J., Nowak, R. P., Fischer, E. S., Gray, N. S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11429-w · Cited by 237
Metadata
- Authors
- Pawlotsky, J.-M., Feld, J. J., Zeuzem, S., & Hoofnagle, J. H.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 62
- Issue
- 1
- Pages
- S87-S99
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2138488044
- Cited by
- 328
- References
- 82
- FWCI
- 30.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.